Additionally, while tau methylation plays a crucial role in Alzheimer’s disease, the lysine methyltransferases involved in tau protein methylation remain poorly understood, limiting the potential application of lysine methylation markers as therapeutic targets in glucose and lipid metabolism diseases. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.